AbCellera Biologics Inc. (ABCL) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $4.10: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum.
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor... Read more
Sell if holding. Engine safety override at $4.10: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.7/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — AbCellera Biologics Inc.
Latest news
- 12 Health Care Stocks Moving In Monday's After-Market Session — benzinga May 11, 2026 neutral
- AbCellera Biologics Q1 EPS $(0.14) Beats $(0.20) Estimate, Sales $8.315M Beat $5.856M Estimate — benzinga May 11, 2026 positive
- Earnings Scheduled For May 11, 2026 — benzinga May 11, 2026 neutral
- Cantor Fitzgerald Initiates Coverage On AbCellera Biologics with Overweight Rating, Announces Price Target of $7 — benzinga May 5, 2026 positive
- AbCellera To Disclose Interim Results From Phase 1 Portion Of Its Study Of ABCL635, Including Observed Safety Profile, P — benzinga Apr 20, 2026 positive
Generated 2026-05-20T20:21:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Clinical-stage biotech: losses expected pre-commercialisation. Quality floor doesn't distinguish R&D investment from operational decay — components above tell the real story.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $4.10: Quality below floor (2.5 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 7.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 19%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $3.77. Score 5.7/10, moderate confidence.
Take-profit target: $8.82 (+117.8% upside). Prior stop was $3.77. Stop-loss: $3.77.
Quality below floor (2.5 < 4.0).
AbCellera Biologics Inc. trades at a P/E of N/A (forward -5.8). TrendMatrix value score: 5.4/10. Verdict: Sell.
14 analysts cover ABCL with a consensus score of 4.1/5. Average price target: $10.
What does AbCellera Biologics Inc. do?AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet...
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.